0001789617-26-000001.txt : 20260203 0001789617-26-000001.hdr.sgml : 20260203 20260203213010 ACCESSION NUMBER: 0001789617-26-000001 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260131 FILED AS OF DATE: 20260203 DATE AS OF CHANGE: 20260203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Heerma Peter CENTRAL INDEX KEY: 0001789617 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36257 FILM NUMBER: 26595829 MAIL ADDRESS: STREET 1: C/O TRAVERE THERAPEUTICS, INC. STREET 2: 3611 VALLEY CENTRE DRIVE, SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Travere Therapeutics, Inc. CENTRAL INDEX KEY: 0001438533 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 262383102 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3611 VALLEY CENTRE DR STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 888-969-7879 MAIL ADDRESS: STREET 1: 3611 VALLEY CENTRE DR STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Retrophin, Inc. DATE OF NAME CHANGE: 20130220 FORMER COMPANY: FORMER CONFORMED NAME: Desert Gateway, Inc. DATE OF NAME CHANGE: 20080625 4 1 form4-02032026_090207.xml X0508 4 2026-01-31 0001438533 Travere Therapeutics, Inc. TVTX 0001789617 Heerma Peter C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DRIVE, SUITE 300 SAN DIEGO CA 92130 false true false false CHIEF COMMERCIAL OFFICER 0 Common Stock 2026-01-31 4 A 0 26120 0 A 139133 D Common Stock 2026-02-03 4 S 0 7310 32.12 D 131823 D Employee stock option (right to buy) 33.095 2026-01-31 4 A 0 69640 0 A 2036-01-31 Common Stock 69640 69640 D Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. /s/ Elizabeth E. Reed, Attorney-in-Fact 2026-02-03